ProBiotix Health, a UK-based company focused on probiotics for cardiometabolic health, has secured an exclusive supply agreement with Kemin China Technology (KCG) to distribute ProBiotix’s probiotic strain LPLDL in China, Hong Kong, and Macau.
Under the agreement, KCG will market and sell LPLDL as an ingredient for supplement manufacturers, while ProBiotix retains the rights to sell finished consumer products under its own brand in the region.
Kemin China Technology operates as a subsidiary of Kemin Industries, a multinational ingredients supplier with a presence in over 120 countries and annual revenues exceeding $1bn. The agreement marks ProBiotix’s latest effort to strengthen its international distribution network.
ProBiotix CEO Steen Andersen said: “With the huge prevalence of cardiovascular disease in China, we are delighted to have secured this important, long-term collaboration with KCG, which should provide a significant and sustainable revenue stream to both companies.
“It provides scope to expand our sales of LPLDL in what is a key market for us, through a well-established partner with a strong industry brand. It also complements the recent agreement between ProBiotix and Dancare, who sell and distribute finished products.
“As confirmed by our recent trading update, we continue to see ongoing momentum in the business and look forward to updating shareholders on our progress.”
KCG president Dr Gan Zhilin said: “We are glad to partner with ProBiotix in cardiovascular health to address this global health challenge.
“Relying on ProBiotix’s cutting-edge research in the field of probiotic technology and remarkable achievements in improving cardiovascular health, combined with the rich resources of KCG in the Chinese market, we are committed to providing consumers with more efficient and safer cardiovascular health solutions.
“This cooperation not only realises the strong combination of technological advantages of both sides, but also the firm practice of our “healthy China” strategy.”
In October last year, ProBiotix expanded its commercial footprint with a partnership in Mexico. The company signed a distribution agreement with Raff, a supplier of raw materials and ingredients. Founded in 1999, Raff specialises in the distribution of lactic and probiotic cultures, rennet, enzymes, and preservatives for the dairy and nutraceutical sectors.
During the same month, ProBiotix established a commercial partnership with Ukraine-based pharmaceutical distributor Deutsch-Pharm.
Under the arrangement, Deutsch-Pharm will introduce two ProBiotix products under its own brand: YouBiotixX3, designed for cholesterol management, and YourBiotixVH, formulated for vascular health.
